Decision Support for Vaccine Hesitancy

Overseen By Michelle Goryn

Age: Any Age

Sex: Any

Trial Phase: Academic

Sponsor: Johns Hopkins Bloomberg School of Public Health

Compensation: Varies

Number of Visits: Unknown

1200 Participants Needed

Trial Summary

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment LetsTalkShots for addressing vaccine hesitancy?

The LetsTalkShots treatment uses personalized communication strategies, including lived experiences and informational animations, to address vaccine hesitancy, applying behavioral theories to tailor messages effectively. Similar approaches, like motivational interviewing and strong healthcare provider recommendations, have shown promise in improving vaccine uptake, suggesting that LetsTalkShots may also be effective. ^{1 2 3 4 5}

Is LetsTalkShots safe for humans?

The research does not provide specific safety data for LetsTalkShots, as it is a communication tool rather than a medical treatment. ^{1 6 7 8 9}

How does the treatment 'Decision Support for Vaccine Hesitancy' differ from other treatments for vaccine hesitancy?

This treatment is unique because it uses personalized communication strategies, such as tailoring messages to individual experiences and using credible sources, to address vaccine hesitancy. Unlike traditional education methods, it applies behavioral theories to deliver the right message from the right messenger to the right person, making it more effective in changing attitudes towards vaccines. ^{1 2 4 6 10}

What is the purpose of this trial?

The goal of this project is to establish the technical feasibility of a scalable, integrated platform to improve patient informed decision-making and increase vaccine uptake and to evaluate the effectiveness of the integrated platform to improve vaccine uptake.

Research Team

Daniel Salmon, PhD

Principal Investigator

Johns Hopkins Bloomberg School of Public Health

Eligibility Criteria

This trial is for individuals who are hesitant or refuse vaccines. It aims to improve vaccine acceptance by using a platform that reminds patients of appointments and provides decision support tools for both patients and providers.

Inclusion Criteria

Patient has an upcoming appointment in 2 business days at Children's Healthcare of Atlanta Hughes Spalding Primary Care Clinic

My contact information is up-to-date in my health records.

I am due for a COVID-19 vaccine according to my health records.

Exclusion Criteria

N/A

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Providers participate in CME sessions and parents receive tailored vaccine messaging through the LTS platform

Up to one year

Multiple visits as per appointment schedule

Follow-up

Participants are monitored for vaccine uptake and provider adoption of the integrated platform

Up to one year

Treatment Details

Interventions

• LetsTalkShots

Trial Overview The study tests an integrated platform with two main features: 'LetsTalkShots', which offers decision support to patients and healthcare providers, and an appointment reminder system, all within the electronic health record (EHR) system.

Participant Groups

Group I: Patient-Facing CDS Only Experimental Treatment 2 Interventions

Among patients without a MYchart account, those with odd birthdates will receive a link to the LTS website (patient-facing CDS) but no integration into the provider workflow.

Group II: Patient- and Provider-Facing CDS Experimental Treatment 3 Interventions

Parents of patients with odd birthdates (e.g. April 13) and vaccines due at the index appointment who also have a MYchart account will receive a text message directing the parent to the LTS server with integration into the provider workflow

Group III: Control (MYchart account) Placebo Group 1 Intervention

Patients with an even birthdate (e.g. April 14) who have a MYchart account will receive a regular text message and e-mail appointment reminder with a vaccine primer (e.g. "Vaccines are due and reserved for the participant's child"), but no patient- or provider-facing CDS.

Group IV: Control (no MYchart account) Placebo Group 1 Intervention

As in the other control group, those without a MYchart account and an even birthdate (e.g. April 14) will receive a text message and e-mail appointment reminder with a vaccine primer but no patient- or provider-facing CDS.

Who Is Running the Clinical Trial?

Johns Hopkins Bloomberg School of Public Health

Lead Sponsor

Trials

441

Recruited

2,157,000+

Emory University

Collaborator

Trials

1,735

Recruited

2,605,000+

Children's Healthcare of Atlanta

Collaborator

Trials

172

Recruited

108,000+

Findings from Research

Vaccine hesitancy remains a significant issue globally, affecting 15-35% of parents even among those with well-vaccinated children, despite strong evidence supporting vaccine safety and effectiveness.

Health care provider recommendations are crucial for increasing vaccine uptake, with stronger, more assertive language (like presumptive announcements) leading to higher vaccination rates compared to softer, conversational approaches.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

How health care providers should address vaccine hesitancy in the clinical setting: Evidence for presumptive language in making a strong recommendation. Jacobson, RM., St Sauver, JL., Griffin, JM., et al.[2021]

References

1. Switzerland pubmed.ncbi.nlm.nih.gov

LetsTalkShots: personalized vaccine risk communication. [2023]

2. United States pubmed.ncbi.nlm.nih.gov

Improving Conversations With COVID-19 Vaccine Hesitant Patients: Action Research to Support Family Physicians. [2022]

3. United States pubmed.ncbi.nlm.nih.gov

How health care providers should address vaccine hesitancy in the clinical setting: Evidence for presumptive language in making a strong recommendation. [2021]

4. United States pubmed.ncbi.nlm.nih.gov

Addressing the Challenges of Vaccine Hesitancy Broadly and Related to COVID-19 Vaccines. [2022]

5. United States pubmed.ncbi.nlm.nih.gov

Web-based Social Media Intervention to Increase Vaccine Acceptance: A Randomized Controlled Trial. [2021]

6. United States pubmed.ncbi.nlm.nih.gov

Estimating Vaccine Hesitancy in Colorado by Using Immunization Information System Data. [2023]

7. Switzerland pubmed.ncbi.nlm.nih.gov

Megastudies: A New Approach to Reducing Vaccine Hesitation Worldwide. [2023]

8. Canada pubmed.ncbi.nlm.nih.gov

Rhetorical Appeals and Tactics in New York Times Comments About Vaccines: Qualitative Analysis. [2021]

9. United States pubmed.ncbi.nlm.nih.gov

Detecting adherence to the recommended childhood vaccination schedule from user-generated content in a US parenting forum. [2021]

10. United States pubmed.ncbi.nlm.nih.gov

Barriers of Influenza Vaccination Intention and Behavior - A Systematic Review of Influenza Vaccine Hesitancy, 2005 - 2016. [2023]